A double-blind, randomized, placebo-controlled, active reference study of Lu AA21004 in patients with major depressive disorder

Discovery of 1-[2-(2,4-Dimethylphenylsulfanyl)phenyl]piperazine (Lu AA21004): A Novel Multimodal Compound for the Treatment of Major Depressive Disorder

(2011) Benny Bang-Andersen et al.   JOURNAL OF MEDICINAL CHEMISTRY

Pharmacological Blockade of 5-HT7 Receptors as a Putative Fast Acting Antidepressant Strategy

(2011) Ouissame Mnie-Filali et al.   NEUROPSYCHOPHARMACOLOGY

P.2.d.013 Electrophysiological study of the effects of the novel antidepressant Lu AA21004 on the rat 5-HT neuronal activity

(2009) N. Haddjeri et al.   EUROPEAN NEUROPSYCHOPHARMACOLOGY

Sexual Dysfunction, Depression, and the Impact of Antidepressants

(2009) Sidney H. Kennedy et al.   JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY

P.2.b.015 Lu AA21004: a novel potential treatment for mood disorders

(2008) N. Moore et al.   EUROPEAN NEUROPSYCHOPHARMACOLOGY

A regulatory Apologia — A review of placebo-controlled studies in regulatory submissions of new-generation antidepressants

(2008) Hans Melander et al.   EUROPEAN NEUROPSYCHOPHARMACOLOGY

Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial

(2008) René S Kahn et al.   LANCET